103 results about "Cognitive diseases" patented technology

The invention discloses a cognitive disorder nostalgic audio-video intervention therapy method, which comprises the following steps of: building a scene containing nostalgic music art, classical movies and retro original sound, playing matched audio and visual materials to a patient, and guiding the patient to perform structured intervention activities such as puzzle, theme recall or emotion sharing. Therefore, memory is stimulated, cognition is exercised, and emotion expression is promoted; according to the invention, by integrating three layouts of audios of nostalgic music art, classical movies and retro original sounds with matched visual elements, a multi-scene nostalgic sensory environment is constructed, and auditory and visual channels of a patient can be synchronously stimulated; compared with single auditory or visual stimulation, the compound sensory stimulation can more effectively activate a plurality of brain areas related to memory and emotion in the brain, so that long-term memory of deep sleep is more intensively aroused, and the strength and awakening efficiency of reminiscence stimulation are greatly improved.

The invention discloses a hybrid federal learning modeling method and device for a neurocognitive impairment evolution trajectory, and the method comprises the steps that a child node receives an expert global model distributed by a central node, and the expert global model is determined by the central node from an expert global model group according to metadata pre-registered by the child node; taking the expert global model as an initial model, and performing localization training by using the local multi-modal non-invasive physiological signal data to obtain a trained local model; extracting global sharing parameters in the trained local model, and uploading the global sharing parameters to a central node; and for the corresponding expert global model, the central node aggregates global shared parameters uploaded by all the child nodes training the expert global model to obtain an updated corresponding expert global model, issues the updated expert global model to the child nodes, and circulates until a termination condition is met. According to the method, the heterogeneous data of the child nodes are adapted, privacy is protected, and the adaptability and accuracy of trajectory prediction are improved.

The invention discloses a big language model credible reasoning system and method based on double-flow cognitive loss and solution synthesis, and aims to solve the problem of'compliance illusion 'caused by the fact that a big language model cannot process internal and external knowledge conflicts. The invention provides a double-flow cognitive engine, which is used for executing a'this-my 'flow of internal knowledge of a simulation model and a'super-my' flow strictly following an external document in parallel so as to generate two opposite cognitive state vectors. The system calculates a semantic conflict score between the two vectors in real time through a cognitive disorder detector. When the conflict is significant, the system activates and demodulates the synthesis module, and actively generates a text for solving the conflict; when there is no conflict, the output of the "super-my" stream is continued to ensure factuality. According to the method, cognitive conflicts are explicitly and actively solved, and a large language model is transformed into an inference engine with inherent critical thinking and high credibility.

The invention discloses a risk assessment method for rheumatoid arthritis accompanied with cognitive impairment based on big data, and belongs to the field of data feature extraction, and the method specifically comprises the steps: carrying out the unified calling of collected clinical, laboratory and iconography features as an original feature set, and completing the preprocessing through multiple interpolation and Z-score standardization; inputting the original feature set into a self-attention network, and generating interaction feature representation for mining high-order interaction; low-dimensional potential feature vectors are compressed, and combined training is carried out through reconstruction and discriminant loss; inputting the potential feature vectors into an XGBoost model, and screening out a preliminary candidate feature subset; performing global and local importance evaluation on the candidate feature subsets by adopting SHAP, and iteratively rejecting features of which the contribution degrees are lower than a threshold value epsilon until the final feature subset is stable; and respectively inputting the final feature subsets into the simplified ResNet and LightGBM to obtain two groups of risk scores, and then generating a fusion risk score through weighted fusion.

Provided is a Bifidobacterium breve for improving an aging-related cognitive disorder and use thereof. The Bifidobacterium breve for improving the aging-related cognitive disorder is named Bifidobacterium breve BBr16 strain with a deposit number CGMCC No. 24471. The strain can significantly improve the aging-related cognitive disorder and can be used for preparing a product with an efficacy of preventing, improving or treating the aging-related cognitive disorder.

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition for improving cognition, emotion, memory and depression states and a preparation method and application thereof. The traditional Chinese medicine composition is prepared from the following components in parts by mass: radix scutellariae, rhizoma coptidis, radix puerariae, rhizoma anemarrhenae, bitter gourd, rhizoma zingiberis, stiff silkworm, American ginseng and radix notoginseng. Wherein the radix scutellariae and the rhizoma coptidis are monarch drugs and mainly attack the core pathogenesis; the radix puerariae, the rhizoma anemarrhenae and the pseudo-ginseng serve as ministerial drugs, assist monarch drugs and treat secondary pathogenesis; bitter gourd, rhizoma zingiberis, stiff silkworm and American ginseng are used as adjuvant drugs to regulate drug properties and treat and treat both symptoms and root causes; and radix puerariae and pseudo-ginseng are used as conductant drugs for guiding channels or harmonizing the drugs. The traditional Chinese medicine composition disclosed by the invention can be used for preventing and treating cognitive disorder, mood disorder and depressive state caused by metabolic disorder. The traditional Chinese medicine composition is small in side effect, high in individuation and suitable for being taken for a long time, and has an obvious treatment effect.

The invention discloses a cognitive disorder recognition system and method based on audio and video modal decoupling representation learning, and the system comprises an integrated processing and display terminal module which is used for operating data, presenting visual stimulation, controlling a collection process, and preliminarily storing data; the visual stimulation presentation and task instruction module is used for clearly and standardly displaying a preset cognitive evaluation task to the participant and informing the participant of specific operation needing to be completed; the audio and video synchronous acquisition module is used for capturing dynamic visual information when a participant executes a task and acoustic information when the participant executes the task; the cognitive state and auxiliary information input module is used for allowing an operator to input information; the control and management module is used for realizing standardized operation and ensuring consistency and high efficiency of data acquisition; and the cognitive impairment recognition module is used for performing multi-modal analysis processing on the data. The early cognitive impairment screening method can provide efficient, accurate and generalizable early cognitive impairment screening for the elderly groups in the community.

The invention discloses application of lactobacillus rhamnosus to preparation of a product for improving and treating cognitive impairment. The invention discloses the new application of the rhamnosus cheese for the first time, and the rhamnosus cheese can improve or treat cognitive impairment related to aging by improving behavioral function change, brain inflammatory factors, oxidative stress activity and neurotransmitter level caused by aging of mice and regulating transcriptome, intestinal microbiome, metabolome and the like. The lactobacillus rhamnosus has a potential application prospect in the aspect of improving learning and memory ability impairment caused by senescence.

The invention relates to the technical field of traditional Chinese medicine compositions, in particular to a traditional Chinese medicine composition and application of the traditional Chinese medicine composition in preparation of drugs for improving sleep disorder and treating mood disorder or cognitive disorder. The invention provides a traditional Chinese medicine composition. The traditional Chinese medicine composition comprises the following components in parts by mass: 20-30 parts of lycium ruthenicum, 30-40 parts of nitraria fruit, 15-25 parts of gastrodia elata, 13-25 parts of hyperforin perforatum and 2-6 parts of lycopene. The traditional Chinese medicine composition provided by the invention is prepared from lycium ruthenicum, nitraria fruit, gastrodia elata, hyperforin perforatum and lycopene according to a specific ratio, and the composition can effectively relieve anxiety behaviors of chronic stress bound anxiety model mice through ways of resisting oxidation and inflammation, regulating expression of neurotransmitters and the like, prolong sleep time and improve sleep quality. The learning ability and the memory ability of cognitive impairment mice induced by scopolamine are improved, and the neuron density of brain tissues is increased, so that the neuroprotective effect is achieved.

The invention relates to the field of disease testing equipment, in particular to modularized testing equipment for cognitive disorder testing, which comprises a testing round table, the tabletop of the testing round table is provided with a plurality of testing positions arranged in an annular array, and each testing position is detachably provided with entity testing equipment; the baffle is arranged on the periphery of the testing round table in a surrounding mode, the baffle is provided with operation windows which are higher than and matched with the height of the table top of the testing round table, and each operation window is provided with a correlation sensor. According to the modularized testing equipment, a traditional touch control type test can be changed into an entity test, a tested object can be modularized, and an object to be tested can be selected and rapidly changed according to people with different cognitive impairments.

The invention relates to an application of propylamine bromide (C23H30BrNO3) in the treatment of sleep disorder, in particular to an application of propylamine bromide (C23H30BrNO3) in the treatment of sleep disorder. Existing sleep drugs are generally ineffective to sleep disorders related to circadian rhythm, and benzodiazepine and non-benzodiazepine hypnotics have significant side effects such as dependency, cognitive disorder and dizziness, so that long-term use of the traditional sleep drugs is limited. According to the invention, a per3 gene defect zebrafish model is used for drug screening, and a new application of a clinically used drug, namely propylamine bromide, in preparation of drugs for treating sleep disorders is provided for the first time, especially those which are insensitive to existing sedative drugs or related to circadian rhythm disorder, and have no toxic or side effects on sleep disorders. The optimal curative effect can be achieved in the indications by 20 mu M, the sleep-awakening cycle disorder caused by PER3 defects is improved, and the normal sleep-awakening cycle is recovered.

Combination compositions of Compound 1 and fesoterodine for use in the treatment of neurological disorders, such as schizophrenia, Alzheimer's disease psychosis, Parkinson's disease psychosis, cognitive in Alzheimer's disease, psychosis in Lewy body dementia, bipolar disorder, and dyskinesia, are described.

Methods and compositions for treating chemotherapy induced cognitive disorders, e.g., cognitive impairment, are provided. The compositions used in the methods include blood plasma and blood plasma fractions derived from blood plasma with efficacy in treating chemotherapy induced cognitive disorders.

The purpose of the present invention is to assist in making plans for preventing weakness, MCI, and cognitive disorders, which are suitable for improving the state of a user, on the basis of Evidence-based. The present invention is a lifestyle proposal recommendation device for supporting the formulation of a weakness, MCI, and cognitive disease prevention plan for supporting the formulation of a weakness, MCI, and cognitive disease prevention plan, the lifestyle proposal recommendation device being provided with: an initial state information acquisition unit for acquiring initial state information relating to the state of a user who requires prevention of weakness or the like at a specific point in time; a target information acquisition unit for acquiring target information; a prevention content information acquisition unit such as weakness for acquiring prevention content information such as weakness; and a prognosis prediction model that is generated by performing machine learning on basic prevention content information relating to the content of the prevention of the weakness and the like used by an experiencer who previously uses the prevention of the weakness and the like, and basic state information relating to the state of the experiencer who previously uses the prevention of the weakness and the like. And a prognosis prediction unit that, on the basis of the initial state information and prevention content information such as weakness of the user, predicts the prognosis state of the user after a specific period from the specific point in time, said prognosis state being related to the target, and outputs prognosis state information related to the prognosis state.

1. The name of the design product: cognitive disease area door sign. 2. The use of the design product: used as space identification, helping cognitive disease elders to quickly identify the room. 3. The design points of the design product: in shape. 4. The picture or photo that best indicates the design points: combined state front view.

The invention relates to a composition comprising at least 50 mg / g of one or more omega-3 fatty acids, at least 10 mg / g of one or more xanthophylls, at least 1 mg / g of one or more sterols and at least 2 μg / g of one or more phycoprostanes, and to the use of said composition in particular as a food supplement for the prevention of the onset of cognitive disorders.

This invention pertains to the prevention and treatment of aging-associated disease. The invention relates to the use of benzodioxane inhibitors of leukotriene production through modulation of leukotriene A4 hydrolase (“LTA4H”) to treat and / or prevent conditions associated with aging such as cognitive disorders, motor disorders, and neuroinflammation.

This invention provides in some aspects, combinations, compositions and kits comprising a psychedelic drug and an NMD A receptor agonist and applications and uses of same for treating, reducing the incidence of, reducing the severity of or improving a pathology of a subject with a neurologic disease or disorder, a neurocognitive disease or disorder, or a motor disease or disorder, or for enhancing neuroplasticity in a subject with a neurologic disease or disorder, a neurocognitive disease or disorder, or a motor disease or disorder making use of the combinations, compositions and kits of this invention.

The invention provides an early biomarker for cognitive impairment of Parkinson's disease, application of the early biomarker and an intelligent analysis system for Parkinson's disease. The biomarker is a GALC gene. The intelligent analysis system for the early biomarkers of the cognitive impairment of the Parkinson's disease comprises a data integration module and a data analysis module. The data integration module is used for acquiring a gene detection result, an olfactory test score and neuroimaging data of the Parkinson's disease biomarker; and the data analysis module is used for analyzing the influence of gene variation of the Parkinson's disease biomarker on olfactory dysfunction and cognitive decline of the Parkinson's disease patient by adopting a structural equation model SEM based on the multi-modal data set. According to the application, through confluence analysis of multi-modal data, by combining genetics, neuroimaging and clinical evaluation, the rs8005172 site variation of the GALC gene is taken as an early biomarker of cognitive impairment of Parkinson's disease, so that PD patients with high cognitive decline risk can be accurately identified.

Methods and systems for improving medical conditions by delivering a focused ultrasound signal to target sites of the brain. The focused ultrasound signal can have a mechanical index of between about 1.0 to about 8.0 and / or an acoustic pressure of between about 1.0 MPa to about 3.0 MPa. The medical condition can comprise addiction (including binge eating), anxiety disorders and anxiety associated disorders, tinnitus, neurodegenerative disorders, neuropsychiatric disorders, cognitive disorders, neurodevelopmental disorders, post-traumatic stress disorder, stroke recovery, and combinations thereof.

The invention discloses an interactive cognitive impairment detection device, which is applied to the technical field of postoperative cognitive impairment detection.The interactive cognitive impairment detection device is provided with a display controller, virtual reality interactive glasses, a tactile feedback device and an interactive cognitive impairment detection system, so that a medical worker can perform interactive cognitive impairment detection work with a patient; visual, listening, touching, sniffing and other feelings can be added, the situation that the cognitive function of the patient is evaluated only through languages, charts, characters and the like is avoided, therefore, comprehensive judgment can be conducted through added visual cognition, touch, hearing and even smell, the cognitive level of the patient can be judged more accurately, the limitation of the cultural level of the patient on the test is avoided as much as possible, and the test efficiency is improved. Moreover, interaction with the patient can be added, so that more accurate evaluation is realized, and the occurrence proportion and degree of the postoperative cognitive impairment of the patient can be evaluated more accurately and scientifically.

The application discloses a cognitive disorder screening method and system based on resting state electroencephalogram and multi-task paradigm, wherein the method comprises the following steps: collecting baseline closed-eye resting state electroencephalogram signals of a subject under a task-free stimulation condition to establish an individualized neural steady state reference; presenting a multi-dimensional cognitive task covering multiple cognitive function networks; collecting closed-eye resting state electroencephalogram signals in a preset time threshold after the task ends to represent the steady state regression process after neural disturbance. Based on the baseline and recovery period electroencephalogram signals, the neural recovery amplitude feature, the neural recovery rate feature and the brain network reconstruction feature are calculated, the neural recovery feature set is mapped to the healthy neural recovery norm space, the deviation degree of the neural steady state regulation ability is evaluated, and the cognitive disorder risk assessment result is output. The application overcomes the problem of insufficient sensitivity of the traditional resting state or task state single analysis mode to early cognitive disorders, and is suitable for early screening and clinical auxiliary evaluation of cognitive disorders.

The application relates to the technical field of cognitive disorder behavior monitoring, in particular to a cognitive disorder behavior monitoring and early warning method for Alzheimer's disease, which acquires gait parameters of each gait of an Alzheimer's disease patient, screens abnormal gaits, clusters the abnormal gaits based on distance measurement between any two abnormal gaits, obtains a plurality of class clusters, acquires gait disorder features of each class cluster, obtains gait turning features of each class cluster based on differences in disorder conditions between adjacent gaits in each class cluster, fuses the gait disorder features and the gait turning features of each class cluster, determines cognitive disorder behavior indexes of the Alzheimer's disease patient in combination with time intervals between adjacent class clusters, and performs early warning. Compared with a manual observation mode, the application comprehensively analyzes gaits of the Alzheimer's disease patient from multiple aspects, so that accurate cognitive disorder behavior monitoring results can be obtained.

Cannabinoid analogs may exhibit anti-inflammatory properties such as by inhibition of cannabinoid type 2 (CB2) receptors. Pharmaceutical compositions comprising the cannabinoid analogs may be used to treat various diseases and conditions in mammals, including pain, anxiety, a sleep disorder, addiction, epilepsy, depression, post-traumatic stress disorder or Alzheimer's disease. In some examples, the pharmaceutical compositions may be administered for treating a cognitive disorder or for improving cognition.

The present disclosure relates generally to medical imaging and, more particularly, it relates to methods and systems for performing processing of magnetic resonance (MR) imaging of the brain which may be useful in the diagnosis of cognitive disorders. More specifically, the invention includes methods for processing cortical diffusion data from a region of a subject's brain, comprising determining values for the Axial Columnar Refraction (ACR) using values for AngleR and Axial Diffusivity.

The invention relates to a compound as shown in a formula (I), a stereoisomer, a tautomer, an isotope label, nitrogen oxide, a solvate, a polymorphic substance, pharmaceutically acceptable salt or prodrug of the compound, a preparation method of the compound, and a pharmaceutical composition of the compound and the stereoisomer, the tautomer, the isotope label, the nitrogen oxide, the solvate, the polymorphic substance and the pharmaceutically acceptable salt or prodrug. In particular, the compounds are NK-3 receptor antagonists, the compound can be used for preventing and / or treating depression, anxiety disorder, psychosis, schizophrenia, psychotic disorder, bipolar disorder, cognitive disorder, Parkinson's disease, Alzheimer's disease, attention deficit hyperactivity disorder, pain, convulsion, obesity, inflammatory diseases, vomiting, pre-eclampsia, airway-related diseases, reproductive disorders, contraception and sex hormone dependent diseases, and can be used for preventing and / or treating diseases such as chronic bronchitis and chronic bronchitis. , gynecological diseases, and climacteric syndrome.

The application discloses a cognitive disorder screening device and method based on a VR eye tracker and a brain-computer interface, and the device comprises a virtual reality scene generation module, an eye tracker data acquisition module, a brain-computer interface data acquisition module, a data analysis processing module and a cognitive disorder screening module. The virtual reality scene generation module is used for generating a virtual reality scene containing a cognitive task. The data analysis processing module is used for analyzing and processing the acquired eye movement data information set and electroencephalogram signal information set, and extracting a characteristic parameter sequence. The cognitive disorder screening module is used for performing cognitive disorder screening processing on the characteristic parameter sequence, and obtaining cognitive disorder information of a user. The cognitive disorder information comprises information about whether there is a cognitive disorder and a cognitive disorder degree.